Salesforce has agreed to buy Mulesoft, a portfolio company that has more than doubled in value since its 2017 IPO, in a deal with an enterprise value of $6.5bn.

Boston Scientific has bought Emcision, a spinout from Imperial College London that is developing a range of surgical instruments.

The cancer immunotherapy developer, backed by Stanford University, has closed the offering after the underwriters bought another $18m of shares.

DocuSign, valued at $3bn as of its last funding round, has confidentially filed for an initial public offering that would offer exits to more than a dozen corporate investors.

The cancer immunotherapy developer, backed by GV, Celgene, Novartis and Taiho Ventures, has closed the offering after the underwriters bought another $18m of shares.

The Aptus Therapeutics-backed neurodegenerative disorder drug developer has filed for an $80.5m initial public offering on Nasdaq after raising roughly $30m in VC funding.

Prexton Therapeutics, a Parkinson's disease-focused spinoff of Merck Group that had raised $41m in funding, has agreed to an acquisition that could reach more than $1.1bn in size.

The Alphabet and Dell-backed cloud security software provider saw its stock more than double on the first day of trading and now has a market cap of almost $3.9bn.

Cloud security software developer Evident.io, which had raised about $49m from investors including GV, has agreed to an acquisition by Palo Alto Networks for $300m in cash.